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range, 130–180 g/l), raised C ‑reactive protein level 
(175 mg/l; reference range <5 mg/l), and antinu‑
clear antibodies titer of 1/160, as well as emphy‑
sematous pulmonary changes and myelodysplasia 
with no excess of blasts on bone marrow biopsy.
In 2017, he was admitted to the hospital twice 
because of perichondritis of left ear accompanied 
by vertigo, hoarse voice, nasal tenderness, and er‑
ythema nodosum. Positron emission tomography 
(PET) and computed tomography (CT) showed 
increased fluorodeoxyglucose (FDG) uptake in 
the right posterior nasopharynx wall and 2 hyper‑
metabolic lung consolidations in the right upper 
and lower lobe, but no uptake in the cartilage of 
the ears, nose, or tracheobronchial tree (FIGURE 1A). 
Prednisolone 30 mg/d was initiated for an unde‑
termined autoimmune disorder. The weight, fa‑
tigue, arthritis, anemia, and inflammatory mark‑
ers improved quickly and prednisolone was ta‑
pered to 15 mg/d. Following subsequent admis‑
sions with cough, dyspnea, and raised inflamma‑
tory markers, chest CT scan was performed and 
showed bilateral lung consolidations with features 
of organizing pneumonia, traction bronchiectasis, 
mediastinal adenopathy, and bilateral peripher‑
al pulmonary embolism (FIGURE 1B). Pseudomonas 
aeruginosa and Klebsiella pneumoniae were iden‑
tified in bronchoalveolar lavage fluid.
In 2018, after reducing the dose of predniso‑
lone to 10 mg/d the patient developed deafness 
and vestibular neuronitis with no cause identi‑
fied at the time. Further presentation with acute 
kidney injury (serum creatinine, 246 µmol/l) led 
to a kidney biopsy revealing tubular interstitial 
inflammation with early fibrosis, IgG4 positive 
lymphoplasmocytes (10% to 15% per high ‑power 
field), and IgG4 positive staining of the tubular 
basement membrane. Serum IgG4 levels were 
raised at 481 mg/dl (normal values <135 mg/dl). 
PET ‑CT showed positive FDG uptake in the right 
Introduction Relapsing polychondritis (RP) and 
immunoglobulin G4–related disease (IgG4 ‑RD) 
are rare multi ‑organ immune ‑mediated diseas‑
es. Both can present with nonspecific symptoms 
of fatigue, weight loss, arthralgia, raised inflam‑
matory markers, or chronic anemia, and diagnos‑
tic delay is common. Early recognition and diag‑
nosis are important to minimize morbidity and 
risk of incapacity as both diseases have a poten‑
tially good treatment response.1,2
Relapsing polychondritis is characterized by 
recurrent episodes of inflammation of cartilage‑
‑rich tissues, typically affecting the ear, nose, 
or tracheobronchial tree. First presenting as re‑
current and self ‑limiting episodes of acute in‑
flammation, the disease causes tissue destruc‑
tion and functional impairment, such as deafness 
and respiratory tract stenosis if left untreated.1,3 
IgG4 ‑RD is associated with clinical or radiolog‑
ical masses that can appear in almost every or‑
gan, but predominantly in the salivary and lach‑
rymal glands, lymph nodes, pancreas, lungs, and 
kidneys. The diagnosis is suspected from clinical 
and radiological examination findings and con‑
firmed by histology of the involved tissues, typ‑
ically showing a combination of lymphoplasma‑
cytic infiltrates with a high count of IgG4 ‑positive 
plasma cells, storiform fibrosis, and obliterative 
phlebitis. However, histological diagnostic crite‑
ria vary depending on the organ, and mostly 2 of 
the 3 cornerstone findings are present.2,4
Case report A 78 ‑year ‑old man with a past med‑
ical history of type 2 diabetes, hypertension, dys‑
lipidemia, and an episode of pancreatitis 1 year 
earlier presented in June 2016 with a 6 ‑month 
history of extensor tenosynovitis and arthritis 
of the left wrist, accompanied by fatigue, weight 
loss, and Raynaud phenomenon. He had iron de‑
ficiency anemia, (hemoglobin, 96 g/l; reference 
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submandibular sialadenitis, posterior nasophar‑
ynx PET ‑FDG uptake, hilar and cervical lymph‑
adenopathy, high IgG4 serum titers, tubuloint‑
erstitial nephritis with lymphoplasmacytic infil‑
trates, fibrosis, and high counts of IgG4 ‑positive 
plasma cells. He also fulfilled the latest diagnostic 
criteria for definite IgG4 ‑RD because of the pres‑
ence of localized masses or swellings in multi‑
ple organs (lymph nodes, lungs, submandibular 
gland, kidney), serum IgG4 concentrations above 
135mg/dl (481 mg/dl), and a histologic confirma‑
tion with lymphoplasmacytic infiltrates, fibrosis, 
and more than 10 IgG4 ‑positive plasma cells per 
high ‑power field.2,4
It is difficult to establish with confidence that 
the episodes of pulmonary exacerbations were 
due to IgG4 ‑RD and not RP as both diseases 
can present with shortness of breath, cough, 
and increased sputum production. Lung involve‑
ment in IgG4 ‑RD consists of nonspecific inter‑
stitial pneumonia, organizing pneumonia (as 
in the presented case), or pulmonary consoli‑
dations (as in the presented case).2,4 In RP, pa‑
tients usually present with acute respiratory 
distress caused by tracheobronchial chondritis 
or with symptoms of pneumonia due to infec‑
tions triggered by secondary tracheobroncho‑
malacia and bronchiectasis.1,3 For our patient, 
no CT scan–reported signs of chondritis and no 
pathogenic germs were identified by sputum or 
lower lobe of the lung, in a left cervical lymph 
node, and hila consistent with IgG4 ‑related dis‑
ease (FIGURE 1C). 
On referral to a tertiary center, he was noted to 
have erythema nodosum, left submandibular sial‑
adenitis, C ‑reactive protein level of 100 mg/l, and 
hemoglobin level of 100 g/l. Prednisolone was in‑
creased to 15 mg/d and rituximab 1000 mg at day 
0 and day 14 commenced. Following this, signif‑
icant improvement was noted and prednisolone 
could be tapered below 7 mg/d. His inflammato‑
ry and constitutional symptoms resolved, his re‑
nal function came back to baseline with a serum 
creatinine of 130 µmol/l, and his IgG4 level fell 
below 250 mg/dl.
Discussion We have presented a 78 ‑year ‑old man 
with features of both RP and IgG4–related disease 
(IgG4 ‑RD). There was a lengthy period of diag‑
nostic uncertainty that delayed effective therapy.
He fulfilled McAdam, Damiani, Levine, and 
Michet diagnostic criteria for RP by presenting 
with at least 3 clinical features of RP: auricular 
chondritis, nonerosive seronegative polyarthri‑
tis and sensorineural hearing loss, and a posi‑
tive response to corticosteroids administration. 
In addition, he had constitutional symptoms and 
erythema nodosum.1,3 At the same time, there 
were features of IgG4 ‑RD present: extensor en‑
thesopathy, pancreatitis, lung consolidations, 
FIGURE 1 A – positron 
emission tomography 
(PET) and computed 
tomography (CT) from 
August 2017 showing 
increased fluo rodeoxy- 
glucose uptake (arrows) 
in the right posterior 
nasopharynx wall (left) 
and 2 hypermetabolic 
lung consolidations in 
the right upper (middle) 
and lower lobe (right); 
B – CT scan from January 
2018 showing bilateral 
lung consolidations with 




C – PET -CT from August 
2018 showing increased 
fluo rodeoxyglucose 
uptake (arrows) in left 
neck node (left), right 
lower lobe consolidation 
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is typically associated with RP. Bone marrow bi‑
opsy revealed no fibrosis, venous thrombosis, or 
IgG4 lymphoplasmacytic infiltrate.
To conclude, in complex multisystem presenta‑
tions of inflammatory disease, a broad diagnostic 
approach is required. With further understand‑
ing of pathogenic mechanisms and identification 
of newer phenotypes, traditional approaches to 
definition and classification of multisystem dis‑
ease are being questioned. This represents a chal‑
lenge for the medical community to collate large 
scale cohorts and continue to refine classification 
and diagnostic pathways.
Lessons to be learned The following learning 
points can be emphasized from this case report: 
a) Our patient presented with clear features of 
RP and IgG4 ‑RD once different presentations 
over preceding 3 years were put together; b) re‑
peated admissions for bronchitis or pneumonia 
in patients without prior history of chronic bron‑
chitis and without isolation of pathogenic germs 
should raise suspicion for a possible underlying 
autoimmune disease; c) the need to refer patients 
with rare autoimmune conditions or repeated un‑
explained presentations to reference centers; d) 
the necessity for steroids at adequate doses for 
treatment of RP and IgG4 ‑RD; e) the benefit of 
rituximab in RP, IgG4 ‑RD, or in cases where both 
diseases are present together
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bronchoalveolar lavage; Pseudomonas aeruginosa 
and Klebsiella pneumoniae being commensal bac‑
teria found in the flora of healthy individuals.
Moreover, the patient’s kidney involvement, 
interstitial nephritis, was typical of IgG4‑RD, and 
not RP. In RP kidney involvement is rare and usu‑
ally presents as mesangial expansion, IgA ne‑
phropathy, or crescentic glomerulonephritis.1-4
There are 2 explanations for this patient’s poor 
response to steroid treatment. First, current rec‑
ommendations suggest an initial prednisolone 
dose of 0.6 to 1 mg/kg/d for IgG4 ‑RD and 0.25 
to 1 mg/kg/d for RP for 2 to 4 weeks before grad‑
ual tapering and a maintenance dose higher than 
20 mg/d usually for 2 to 6 months.1-4 Our patient 
weighted 80 kilograms and received an initial 
dose of 0.375 mg/kg/d (30 mg/d) for 4 weeks and 
a dose above 0.25 mg/kg/d (20 mg/d) for 6 weeks 
in total – not reaching currently recommended 
targets. Second, he had all the risk factors for re‑
fractory RP disease and poor prognosis: male sex, 
age at diagnosis above 55 years, myelodysplasia, 
cutaneous involvement, and general symptoms.5
Even though RP and IgG4 ‑RD respond well to 
corticosteroid therapy, treatment for corticore‑
sistant or corticodependent cases differ.1,2 For re‑
lapsing polychondritis, azathioprine, methotrex‑
ate, cyclophosphamide, or infliximab are mostly 
used and rituximab is controversial.1,3 In IgG4‑
‑RD, corticoresistant cases are usually treated 
with azathioprine, mycophenolate mofetil, meth‑
otrexate, or rituximab.2,4 We made the choice to 
treat our patient with rituximab and his good re‑
sponse reinforces the rationale for rituximab in 
patients with RP and IgG4 ‑RD.
The range of features and disease associations 
of IgG4 ‑RD continue to expand, while RP is asso‑
ciated with another autoimmune disease in 30% 
of cases. However, co‑ocurence of RP and IgG4 has 
only been reported in 2 cases where the diagnosis 
of RP preceded the diagnosis of IgG4 ‑RD by 20 
years and 14 months and symptoms resolved with 
steroid treatment.1,6 Our case is the first descrip‑
tion of concomitant occurrence of RP and IgG4‑
‑RD and the first patient who responded well to 
treatment with rituximab.
Finally, in this case, one could question 
the presence of RP and suggest instead that only 
IgG4 ‑RD was present with some atypical RP ‑like 
symptoms. IgG4 ‑RD is described as a “great mim‑
icker” and can present with nasal, sinusal, orbit‑
al, periorbital, salivary, or lachrymal inflamma‑
tory masses.7 However, to the best of our knowl‑
edge, no case of IgG4 ‑RD presenting with peri‑
chondritis of the ears has been described so far, 
except for the 3 cases mentioned here above in 
which this presentation was attributed to RP and 
not IgG4 ‑RD. One of these patients having un‑
dergone an ear biopsy that discarded IgG4 plas‑
mocyte infiltration, fibrosis, or venous embo‑
lism in the ears.6 Moreover, our patient fulfilled 
not one but all 3 existing diagnostic criteria for 
RP. He presented with skin disease typical for RP 
and not IgG4 ‑RD and with myelodysplasia that 
